We expect to see further expansion of our cancer and infectious disease franchises as we strengthen our pipeline through organic development, acquisition and in-licensing.
Sean Lance
acquisition development disease expansion cancer strengthen organic
We believe that this program is in the best interest of our shareholders and we expect that it will offset a substantial part of the dilution associated with the company's employee stock option and stock purchase plans.
plans interest part
You must log in to post a comment.
There are no comments yet.